Non-Hodgkin Lymphoma
Protocol B1931008
Non-Hodgkin Lymphoma
An Open-label, Randomized, Phase 3 Study of Inotzumab Ozogamcin Administered in Combination with Rituximab Compared to Defined Investigators Therapy in Subjects with Relapsed or Refractory CD22-Positive Aggressive Non-Hodgkin Lymphoma Who Are Not Candidates for Intensive High-Dose Chemotherapy
Click here for more Information…
Breast Cancer
Protocol # BAY 43-9006 / 12444
Stage or Phase: Stage 4
A Phase III Randomized, Double-blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Click here for more Information…
Closed Studies
Breast Cancer
Protocol # Novartis CZOL446EUS147
Stage or Phase: Stage IV
A multicenter, open-label, randomized trial to evaluate the anti-cancer effects of zoledronic acid using circulating tumor cell measurements in patients with newly diagnosed HER2-negative metastatic breast cancer
Click here for more Information…
Protocol # GSKMA.31/EGF108919: Randomized, open-label, phase iii study of taxane based chemotherapy with lapatinib or trastuzumab as first-line therapy for women with her2/neu positive metastatic breast cancer
Multiple Myeloma
Millenium C05009: Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE® (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE® and Dexamethasone (VD) versus VELCADE®, Melphalan, and Prednisone (VMP)
Non-Small Cell Lung Cancer
Pfizer A4021016: Randomized, Open label, Phase III trial of CP-751,871 in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer
Sanofi-aventis EFC10261: A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated with Second-Line Docetaxel after Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
Protocol # H3E-MC-JMIG: Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than PredominantlySquamous Cell Histology